Inspection Machines Market Size, Pharma Visual Inspection, AI & Forecast 2035

Inspection Machines Market Size & Forecast 2035

The global inspection machines market was valued at US$1.07 billion in 2025 and is projected to reach US$2.14 billion by 2035, growing at a CAGR of 7.2% during 2026-2035. Demand is being driven by tighter pharmaceutical quality requirements, higher sterile-injectable production, expansion of biologics and prefilled syringes, growing use of automated visual inspection, and integration of machine vision, AI, leak detection and digital batch records into production lines.

Inspection equipment is moving from standalone defect detection toward integrated quality-control platforms. Current machines can combine particle and cosmetic-defect inspection with container-closure integrity testing, fill-level verification, OCR, serialization and production data management. Syntegon's AIM9, launched in February 2026, combines automated visual inspection with optional headspace gas analysis and high-voltage leak detection and can process up to 600 vials per minute.

At the same time, pharmaceutical production is becoming less uniform. High-volume injectable lines still reward maximum throughput, but clinical development, personalized therapies, ATMPs and CDMO operations increasingly require small batches, multiple container formats and rapid validated changeovers. Körber's 2026 ALVA platform was developed specifically for these high-mix, low-volume environments.

Market Highlights

• 2025 Market Size: US$1.07 Billion
• 2035 Market Size: US$2.14 Billion
• CAGR, 2026-2035: 7.2%
• Largest Region: North America
• Fastest-Growing Region: Asia-Pacific
• Leading Product Category: Vision Inspection Systems
• Fastest Automation Shift: Fully Automated Inspection
• High-Growth Packaging Formats: Vials, ampoules and prefilled syringes
• Core End Users: Pharmaceutical manufacturers, biotechnology companies, CDMOs and medical-device manufacturers
• Key Growth Technologies: machine vision, deep learning, X-ray inspection, CCIT, HVLD, headspace analysis, OCR and combination inspection
• Primary Buying Metrics: probability of detection, false reject rate, throughput, changeover time, validation burden, container compatibility and lifecycle service. 

Inspection Machines Are Becoming a Production-Economics Decision

Inspection equipment has traditionally been treated as a quality-compliance purchase. That view is becoming too narrow.

For a high-volume pharmaceutical plant, the inspection machine sits directly inside the economics of the filling and packaging line. A machine with excessive false rejects can discard acceptable high-value drug product. A slow machine can become the line bottleneck. Long format changes reduce equipment utilization, while difficult validation can delay commercial production.

The buying question is therefore shifting from “Can the machine detect defects?” to “Can it detect the required defects at production speed without creating excessive false rejects, downtime or validation workload?”

Modern platforms increasingly combine several inspection operations inside one machine. Mettler-Toledo, for example, offers pharmaceutical systems combining vision, checkweighing and X-ray capabilities while also supporting electronic records, audit trails and validation documentation.

This favors suppliers that can connect mechanical handling, cameras, inspection algorithms, leak testing, software and lifecycle qualification into one validated platform.

Inspection Machines Market Key Takeaways

• The inspection machines market will grow from US$1.07 billion in 2025 to US$2.14 billion by 2035, supported by automated pharmaceutical quality control and expansion of smart manufacturing.
• Vision inspection remains the commercial core of the market. The DMI scope identifies vision inspection as the leading product category, while current platforms increasingly integrate cameras with deep-learning classifiers and complementary leak-detection systems.
• Automation does not eliminate validation requirements. A 2025 pharmaceutical visual-inspection survey found manual inspection remained in use at 86% of responding companies, automated visual inspection at 49% and semi-automated inspection at 44%, showing that manufacturers continue to operate hybrid inspection strategies.
• AI's commercial value is increasingly tied to reducing false rejects. Antares Vision Group's AI-GO platform was developed to classify complex anomalies and reduce unnecessary scrap, while Syntegon offers optional deep-learning capabilities on its newest platforms.
• Container-closure integrity is moving closer to visual inspection. AIM9 can integrate headspace analysis and high-voltage leak detection directly into the inspection line, allowing particulate, cosmetic and leak defects to be evaluated without a separate machine.
• High-mix, low-volume production is creating a distinct equipment category. Körber's ALVA targets syringes, vials and cartridges used in clinical trials, personalized therapies, ATMP production and CDMO environments where frequent product changes make conventional high-speed architectures less efficient.
• Asia-Pacific offers the strongest capacity-growth opportunity. Current market analysis identifies APAC as the fastest-growing region, with India forecast to register an 8.6% CAGR through 2035 as pharmaceutical manufacturing and automated quality-control investment expand. 

Vision Inspection Systems Remain the Market's Largest Product Segment

Vision inspection systems remain the leading product category because they can evaluate several product and packaging attributes simultaneously.

Typical inspections include:

• visible particles
• cosmetic container defects
• cracks and chips
• fill level
• stopper position
• cap and seal condition
• tablet or capsule presence
• blister integrity
• label position
• lot and expiry codes
• OCR/OCV
• serialization codes.

The DMI market analysis identifies vision inspection as the largest product segment because of its adaptability across pharmaceuticals, biotechnology, medical devices and packaging applications.

Current systems are substantially more sophisticated than conventional camera-plus-threshold architectures. Brevetti CEA, for example, offers automatic inspection across syringes, ampoules, vials, cartridges and bottles and integrates its Brevetti AI Studio for deep-learning applications.

The commercial differentiator is increasingly inspection performance on difficult products. Suspensions, oily products, lyophilized cakes, highly viscous drugs and containers with bubbles or strong optical reflections can be harder to inspect than transparent aqueous solutions. Syntegon uses specialized spinning, lighting and optional bubble-masking technologies for these cases.

AI Is Targeting the Most Expensive Inspection Problem: False Rejects

A false reject occurs when the system identifies an acceptable product as defective.

At high throughput, even a small false-reject rate can become expensive because every unnecessary rejection represents lost drug product, packaging material and manufacturing capacity.

This is where deep learning is gaining commercial relevance.

Antares Vision Group launched AI-GO in 2025 as a validated industrial AI platform for visual inspection. The architecture includes a cloud-based model-development environment and an edge runtime that can execute models directly on production equipment. The company positions the system for classification, segmentation and OCR tasks and for identifying defects such as glass fragments, foreign bodies and cosmetic anomalies.

Brevetti CEA has also integrated deep-learning capabilities into its inspection portfolio and completed its acquisition of Brevetti AI in August 2025, strengthening its internal AI capabilities for regulated inspection applications.

AI adoption, however, remains cautious in validated pharmaceutical environments. A 2025 survey found only 1% of respondents were already using AI algorithms in visual inspection, while 27% planned near-term adoption. The limiting issue is not simply model accuracy: pharmaceutical users need representative defect datasets, documented performance, controlled software changes and ongoing monitoring.

This makes validatable AI a stronger commercial proposition than a black-box model delivering a high laboratory accuracy score.

Automated Visual Inspection Does Not Eliminate Manual Inspection

Automation is growing, but the market should not be interpreted as a simple replacement of every human inspector.

FDA's visible-particulate framework treats visual inspection as part of a broader risk-based control strategy for injectable drug products. Visible particulates can present patient-safety risks, and inspection must operate alongside manufacturing controls, particulate investigation and corrective action.

The commercial implication is that manufacturers need systems that can be qualified against an established inspection standard.

The 2025 industry survey found 66% of respondents revalidated automated inspection programs within six to twelve months. This recurring qualification requirement creates ongoing demand for engineering services, test sets, reject libraries, software control and documentation rather than making an inspection machine a one-time capital purchase.

Container Closure Integrity Testing Is Moving Into the Inspection Platform

Visual inspection can identify many container defects, but it cannot reliably detect every microscopic leak.

That creates a separate commercial opportunity around container closure integrity testing (CCIT).

Leak testing is particularly important for sterile vials, ampoules, cartridges and prefilled syringes because closure failure can compromise sterility or product stability even when the package appears visually acceptable.

Syntegon's AIM9 illustrates the move toward integrated CCIT. The system can incorporate headspace gas analysis, high-voltage leak detection or both alongside visual inspection.

Brevetti CEA likewise offers platforms that combine particle and fill-level inspection with leak detection, including its BH-S600 LD and A35 LD systems.

Integration creates a stronger value proposition for manufacturers because separate inspection stages consume additional floor space, validation effort and line controls.

Through 2035, combination platforms that inspect particles + cosmetic defects + closure integrity + fill attributes are likely to capture a larger portion of premium equipment spending.

Prefilled Syringes Are Raising Inspection Complexity

Prefilled syringes require inspection of both the drug product and a mechanically more complex container system.

An inspection program can need to evaluate:

drug solution, particles, barrel defects, flange damage, stopper position, needle shield, plunger components and cosmetic conditions.

This makes gentle handling particularly important because inspection equipment should not create the defects it is intended to detect.

Brevetti CEA's K15 DR combines automatic de-nesting, inspection and re-nesting for prefilled syringes in one platform.

Current market analysis also identifies syringes among the principal packaging formats benefiting from increasing inspection investment, while vials and ampoules are expected to record particularly strong growth.

The growth of ready-to-use syringes and injectable biologics therefore increases demand for inspection machines that can connect directly with nested-container handling systems.

High-Speed Vial Inspection Remains a Major Capital-Equipment Market

Vials remain central to vaccines, biologics, lyophilized drugs and injectable small molecules.

High-volume facilities need inspection systems capable of keeping pace with upstream filling equipment.

Syntegon's AIM9 handles up to 600 vials per minute across container sizes ranging from 2 mL to 250 mL.

Brevetti CEA's current portfolio also includes systems reaching 600 pieces per minute for liquid, freeze-dried and syringe applications.

At these speeds, inspection economics are highly sensitive to:

false rejects, jams, product handling, recipe stability and downtime.

A marginal increase in detection capability is commercially unattractive if it substantially reduces yield or line availability. Premium inspection suppliers therefore increasingly compete on the relationship between probability of detection and false-reject rate, not one metric in isolation.

High-Mix, Low-Volume Production Creates a Different Machine Category

High throughput is not the correct buying criterion for every pharmaceutical manufacturer.

Clinical trials, personalized medicines, ATMPs and some biologics can involve much smaller production runs and frequent format changes.

Körber introduced ALVA in May 2026 specifically for high-mix, low-volume inspection. The fully automatic platform supports syringes, vials and cartridges and is designed around rapid changeovers and compact deployment.

This segment changes equipment economics.

A 600-container-per-minute machine provides little advantage if a manufacturer spends significant time changing formats, validating recipes and cleaning between small campaigns.

HMLV buyers therefore prioritize:

changeover time, recipe management, format flexibility, small-batch validation, compact footprint and rapid product introduction.

CDMOs are particularly important customers because one facility may need to inspect products from numerous sponsors using different container formats.

X-Ray Inspection Extends Detection Beyond the Visible Surface

X-ray inspection addresses defects that conventional cameras cannot always identify.

In pharmaceutical packaging, X-ray can be used for:

• foreign-material detection
• completeness checks
• tablet and capsule counting
• blister verification
• detection within opaque packaging
• identification of glass or dense contamination.

Mettler-Toledo offers X-ray systems alongside vision inspection, checkweighing and metal detection for pharmaceutical quality control, including applications involving vials, blisters, tablets and capsules.

X-ray is therefore not a direct substitute for machine vision. The technologies inspect different physical characteristics.

This creates demand for combination systems where a manufacturer needs to verify appearance, labeling, mass and internal package condition on one line.

Checkweighers Remain Essential Where Weight Is a Critical Quality Attribute

Checkweighers provide a simple but commercially important quality measurement: does the package or product have the expected mass?

Applications include:

• bottle fill verification
• missing tablet detection
• incomplete kits
• syringe or device assembly checks
• package completeness.

High-speed pharmaceutical lines increasingly combine checkweighing with vision or serialization equipment rather than installing each quality-control station as an isolated machine.

The advantage is a smaller footprint and a unified reject-management strategy. Mettler-Toledo's current pharmaceutical portfolio specifically promotes combination inspection architectures for regulated production environments.

Metal Detection Remains Relevant Upstream of Final Packaging

Metal detectors remain important where pharmaceutical powders, granules, tablets or capsules could contain metallic contamination.

They are commonly deployed around powder handling, tablet compression and capsule production.

Current pharmaceutical inspection portfolios use high-sensitivity metal detectors for ferrous, non-ferrous and stainless-steel contamination, while X-ray inspection can cover additional contaminant classes and finished packages.

The strongest commercial opportunity is therefore not metal detection replacing X-ray or vision. It is selecting the correct combination of inspection technologies according to the risk profile of each manufacturing step.

Software Is Becoming Part of the Validated Inspection Asset

Inspection machines increasingly generate large volumes of image, reject, recipe and audit-trail data.

Manufacturers want to use that information for more than pass/fail decisions.

Software can support:

• reject trending
• defect classification
• electronic batch records
• audit trails
• recipe control
• remote diagnostics
• image archives
• model management
• track-and-trace integration.

Antares Vision Group's AI-GO uses separate development and runtime environments, while Stevanato Group is developing digital inspection ecosystems intended to reduce downtime and improve machine performance.

This means the inspection-machines market is acquiring a recurring software and services component.

For vendors, software can deepen customer retention long after initial equipment installation.

Pharmaceutical and Medical-Device Buyers Have Different Inspection Priorities

The DMI market scope divides end users primarily between pharmaceutical and medical-device manufacturers.

Pharmaceutical inspection is heavily influenced by visible particulates, fill level, sterile-container integrity and labeling.

Medical-device inspection places greater emphasis on:

assembly completeness, dimensions, surface defects, component presence, print verification, packaging integrity and traceability.

Both sectors benefit from machine vision, X-ray and checkweighing, but validation and defect taxonomies differ.

This distinction matters commercially because suppliers capable of reusing a common machine-vision architecture across pharmaceuticals and devices can broaden their addressable market without using identical inspection recipes.

North America Remains the Largest Commercial Market

North America holds the largest position in the DMI inspection-machines market, supported by a large pharmaceutical, biotechnology and medical-device manufacturing base and high adoption of automated quality systems.

The United States is particularly important for high-value injectable inspection because FDA expectations extend beyond simple pharmacopoeial compliance. FDA's visible-particulate guidance calls for a holistic, risk-based control strategy covering manufacturing controls, inspection, investigation and corrective action.

This encourages investment not only in cameras but also in data integrity, reject trending, validation and lifecycle quality management.

North American buyers are likely to remain early adopters of AI-assisted inspection, integrated CCIT and software upgrades, but suppliers need to demonstrate that new algorithms can be validated and maintained under controlled change-management procedures.

Europe Is a High-Compliance, High-Automation Market

Europe combines a large pharmaceutical manufacturing base with stringent sterile-manufacturing requirements.

The revised EU GMP Annex 1 is now fully applicable, with the final deferred provision taking effect in August 2024. The framework has increased attention on contamination control, quality-risk management and the use of suitable manufacturing technologies throughout sterile production.

Europe is also home to a dense cluster of leading inspection-equipment companies including Syntegon, Körber, Antares Vision Group, Brevetti CEA and Stevanato Group.

This creates a mature replacement and upgrade market in which machine purchases increasingly focus on AI capability, CCIT integration, higher throughput, compact footprint and validation efficiency rather than first-time automation alone.

Asia-Pacific Is the Fastest-Growing Region

Asia-Pacific is the fastest-growing regional inspection-machines market, supported by expanding pharmaceutical manufacturing and investment in automated quality-control systems.

India is expected to register an 8.6% CAGR through 2035 in the current market benchmark, reflecting continued expansion of pharmaceutical manufacturing, CDMO capacity and quality-system modernization.

China remains important through its large pharmaceutical equipment and drug-manufacturing base, while Japan has a long-established role in high-quality injectable manufacturing and pharmaceutical machinery.

The commercial opportunity is not uniform. Large export-oriented manufacturers can justify premium automated inspection, while smaller manufacturers remain more sensitive to equipment cost and may retain semi-automatic systems for longer.

This price-performance divide makes modular inspection architectures particularly relevant in APAC.

Latin America Offers a Modernization Opportunity

Latin America's market is smaller but benefits from expansion of domestic pharmaceutical manufacturing in Brazil, Mexico and other major economies.

The strongest opportunities lie in replacing manual or older inspection systems with automated vision, checkweighing, serialization and contamination-control equipment.

For global suppliers, service capability is a significant competitive issue. Pharmaceutical plants require rapid technical support and validated spare-parts management, making local engineering coverage an important part of the buying decision.

Middle East & Africa Growth Will Center on New Pharmaceutical Capacity

Middle East and Africa represent a smaller current revenue base but offer greenfield opportunities where countries are investing in domestic pharmaceutical and medical-product manufacturing.

New facilities can adopt automated inspection from the beginning rather than retrofitting systems onto older production lines.

Cost remains a greater constraint than in North America and Western Europe, favoring equipment that provides scalable automation, local service and lower validation complexity. Current market research identifies cost-effective inspection solutions as an important opportunity in underserved manufacturing regions.

Competitive Landscape

Syntegon

Syntegon has one of the broadest current automatic inspection portfolios for injectable pharmaceuticals.

Its February 2026 AIM9 launch combines particle and cosmetic inspection with integrated CCIT options and throughput reaching 600 vials per minute. The platform supports containers from 2 mL to 250 mL and can incorporate deep learning.

Syntegon's competitive strength lies in combining inspection with wider filling, handling and pharmaceutical-processing expertise.

Antares Vision Group

Antares Vision Group competes across quality inspection, track-and-trace and data management.

Its 2025 AI-GO platform integrates cloud model training with edge deployment and targets classification, segmentation, OCR and complex anomaly recognition.

This positions Antares strongly where customers want inspection data integrated with serialization and wider product-traceability infrastructure.

Körber Pharma

Körber's current strategy is differentiated by inspection architectures for both high-speed and flexible pharmaceutical production.

The 2026 ALVA launch targets high-mix, low-volume applications involving syringes, vials and cartridges, with particular relevance to CDMOs, clinical trials, personalized therapies and ATMPs.

The company is therefore competing not only on inspection performance but also on production flexibility.

Stevanato Group

Stevanato Group provides automated inspection across vials, syringes, cartridges and other injectable formats.

Its current portfolio includes the CVT series, CVT Core, Easy and Plus systems, along with the Vision Robot Unit and digital inspection technologies.

Stevanato's additional position in primary drug containers gives it a distinctive ability to connect container design with inspection performance.

Brevetti CEA

Brevetti CEA specializes in automatic visual inspection of injectable products.

Its machines cover vials, ampoules, syringes, cartridges, bottles and blow-fill-seal formats. The company's acquisition of Brevetti AI strengthened its deep-learning capabilities, while its current platforms increasingly combine vision inspection with leak detection.

Mettler-Toledo

Mettler-Toledo competes through a broad product-inspection portfolio covering checkweighing, vision, X-ray and metal detection.

Its value proposition is particularly strong where manufacturers want combination systems, global qualification support and inspection integrated with electronic records and audit requirements.

Jekson Vision

Jekson Vision is an increasingly relevant Asia-based competitor in pharmaceutical vision inspection and serialization.

Its BiSmart 2.0 platform uses AI-supported blister inspection and is positioned for regulated production with GAMP 5 and 21 CFR Part 11 capabilities.

Recent Developments Reshaping the Inspection Machines Market

May 2026 - Körber Launches ALVA

Körber introduced a fully automatic inspection platform designed for high-mix, low-volume pharmaceutical production, including clinical, personalized-therapy, ATMP and CDMO applications.

February 2026 - Syntegon Launches AIM9

Syntegon introduced AIM9 with throughput up to 600 vials per minute and integrated options for headspace gas analysis and high-voltage leak detection.

January 2026 - AI-Based Blister Inspection Advances

Jekson Vision expanded promotion of its BiSmart architecture for AI-supported defect detection in pharmaceutical blister packaging, targeting high-speed lines and difficult packaging formats.

August 2025 - Brevetti CEA Strengthens Deep-Learning Capabilities

Brevetti CEA completed the acquisition of Brevetti AI, formerly Criterion AI, strengthening its ability to develop machine-learning and deep-learning inspection technologies for regulated applications.

June 2025 - Antares Vision Group Introduces AI-GO

Antares launched AI-GO as an AI platform for visual quality inspection, combining cloud model-development tools with an edge runtime for deployment directly on manufacturing lines.

What Pharmaceutical Buyers Should Evaluate Before Purchasing an Inspection Machine

Probability of Detection

Manufacturers should define the critical defect library before comparing equipment.

A high claimed detection accuracy has little value if the test set does not represent the actual particles, cracks, cosmetic defects or closure abnormalities expected on the product.

False Reject Rate

False rejects directly affect yield.

This becomes especially important for expensive biologics and injectables where discarding an acceptable vial or syringe can carry much greater product value than the packaging itself.

Production Throughput

The machine should not become the bottleneck on the filling or packaging line.

High-volume vial operations can require hundreds of containers per minute, while HMLV lines place greater value on changeover speed than maximum continuous throughput.

Container and Product Compatibility

Buyers should verify performance across the actual formulation and container combination.

Clear liquid in a vial presents a different inspection problem from a suspension, lyophilized cake, cartridge or nested prefilled syringe.

CCIT Integration

Combining visual inspection and leak detection can reduce footprint and simplify product handling.

The decision should consider whether HVLD, headspace analysis or another CCIT approach fits the formulation and container.

Validation Effort

Validation workload affects time to production.

Manufacturers should compare qualification documentation, defect-set development, recipe validation, software controls and revalidation requirements rather than equipment price alone.

Changeover Time

CDMOs and HMLV manufacturers should evaluate how long it takes to move between formats, recipes and products.

A lower headline machine speed can produce higher annual utilization if changeovers are much faster.

Data Integrity

Audit trails, user access control, electronic records, recipe management and image archives are increasingly central to regulated inspection systems.

Lifecycle Service

Inspection equipment remains validated production infrastructure for years.

Local service, spare parts, camera replacements, software upgrades, training, and requalification support should be included in total cost of ownership.

Inspection Machines Market Scope